Chemours (CC)
(Delayed Data from NYSE)
$19.79 USD
-0.66 (-3.23%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $19.80 +0.01 (0.05%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$19.79 USD
-0.66 (-3.23%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $19.80 +0.01 (0.05%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth C Momentum F VGM
Zacks News
Sherwin-Williams (SHW) Inks Deal to Buy Gross & Perthun GmbH
by Zacks Equity Research
Sherwin-Williams' (SHW) deal with Gross & Perthun GmbH provides multiple opportunities to boost profitable growth throughout Europe and beyond.
Air Products (APD) Inks Long-Term Supply Deal With IOCL
by Zacks Equity Research
Air Products (APD) will build, own and operate a new industrial gases complex providing hydrogen, nitrogen and steam to IOCL's Barauni Refinery.
ScottsMiracle-Gro (SMG) Lowers Sales and EPS Outlook for FY22
by Zacks Equity Research
ScottsMiracle-Gro's (SMG) adjusted earnings per share are now projected between $4.50 to $5.
Cabot (CBT) Prices 5% Senior Notes Due 2032 Worth $400 Million
by Zacks Equity Research
Cabot's (CBT) notes are being sold to the public at 99.33% of the face amount.
US Chemicals Set for Solid Growth Despite Supply Chaos: 5 Picks
by Anindya Barman
The U.S. chemical industry is poised for strong upside this year on healthy end-market demand and inventory rebuilding. HUN, ALB, KRO, CC and UNVR are good options for investment right now.
Chemours (CC) Stock Hits 52-Week High: What's Driving It?
by Zacks Equity Research
Chemours (CC) benefits from a rebound in demand from the pandemic-induced downturn, strong execution, cost-reduction and pricing actions.
Chemours (CC) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
Chemours (CC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
New Strong Buy Stocks for June 7th
by Zacks Equity Research
SBLK, GOGL, LPX, ASRT, and CC have been added to the Zacks Rank #1 (Strong Buy) List on June 7, 2022.
Best Value Stocks to Buy for June 7th
by Zacks Equity Research
LPX, GOGL, and CC made it to the Zacks Rank #1 (Strong Buy) value stocks list on June 7, 2022.
Is Chemours (CC) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Best Value Stocks to Buy for June 3rd
by Zacks Equity Research
AMR, MBUU, and CC made it to the Zacks Rank #1 (Strong Buy) value stocks list on June 3, 2022.
Cabot (CBT) Shares Hit 52-week High: What's Driving It?
by Zacks Equity Research
Cabot (CBT) is gaining from a recovery in demand and strategic acquisitions.
Why Is Chemours (CC) Up 10.7% Since Last Earnings Report?
by Zacks Equity Research
Chemours (CC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Invest In Chemours (CC) Stock Now
by Zacks Equity Research
Chemours (CC) is gaining from higher volumes on the back of strong demand, its cost and pricing actions and strong execution.
Chemours (CC) Evaluates Capacity Investments for Hydrogen Economy
by Zacks Equity Research
Chemours' (CC) higher ionomers capacity would support demand growth within water electrolysis and fuel cell technology.
Is Chemours (CC) Outperforming Other Basic Materials Stocks This Year?
by Zacks Equity Research
Here is how Chemours (CC) and Gerdau (GGB) have performed compared to their sector so far this year.
Chemours (CC) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Chemours (CC) have what it takes to be a top stock pick for momentum investors? Let's find out.
Chemours (CC) Declares New Process for APA Grade Viton Production
by Zacks Equity Research
Chemours (CC) now has the potential to produce the complete Viton fluoroelastomers portfolio using a non-fluorinated surfactant.
Chemours (CC) Stock Pops 44% in 3 Months: What's Driving It?
by Zacks Equity Research
Chemours (CC) is benefiting from strong end-market demand and its cost-reduction and pricing actions.
Zacks Industry Outlook Highlights Dow, Albemarle, Huntsman and The Chemours
by Zacks Equity Research
Dow, Albemarle, Huntsman and The Chemours have been highlighted in this Industry Outlook article.
4 Stocks to Buy From the Promising Diversified Chemical Industry
by Anindya Barman
An upswing in demand in major end markets should enable the Zacks Chemicals Diversified industry to thrive. DOW, ALB, HUN and CC are set to gain from favorable industry fundamentals and strategic actions to counter cost inflation.
Is Chemours (CC) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks.com featured highlights include Imperial Oil, CF Industry Holdings, The Chemours, Medifast, and APA
by Zacks Equity Research
Imperial Oil, CF Industry Holdings, The Chemours, Medifast, and APA are part of Screen of the Week article.
5 High Earnings Yield Value Picks Amid Market Jitters
by Rimmi Singhi
Value investing should be one of the most effective investment approaches now. IMO, CF, CC, MED and APA are some high earnings yield value stocks to tide over market mayhem.
The Zacks Analyst Blog Highlights Penske Automotive Group, Griffon, Louisiana-Pacific, The Chemours, and Avnet
by Zacks Equity Research
Penske Automotive Group, Griffon, Louisiana-Pacific, The Chemours, and Avnet are part of Zacks top Analyst Blog.